本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Apellis Pharmaceuticals Inc.

27.57
-0.4800-1.71%
盘后27.570.00000.00%16:20 EDT
成交量:155.21万
成交额:4,279.39万
市值:34.82亿
市盈率:-15.11
高:28.20
开:28.12
低:27.36
收:28.05
52周最高:41.94
52周最低:16.10
股本:1.26亿
流通股本:7,811.99万
量比:1.01
换手率:1.99%
股息:- -
股息率:- -
每股收益(TTM):-1.8245
每股收益(LYR):-1.5970
净资产收益率:-108.49%
总资产收益率:-13.77%
市净率:22.28
市盈率(LYR):-17.26

数据加载中...

2025/08/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/08/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/31

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/07/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/01

重要事件披露

Form 8-K - Current report
2025/06/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/06/04

重要事件披露

Form 8-K - Current report
2025/05/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/05/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/04/21

重要事件披露

Form 8-K - Current report
2025/03/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/02/28

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/02/28

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/11

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities